3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
10
Active not recruiting
5
Withdrawn
2
Recruiting
2
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
19
Breast
19
Genitourinary
9
Gastrointestinal
9
Tumor-Agnostic
6
Other solid neoplasm
6
CNS
6
Thoracic
5
NET
3
Endocrine
3
Sarcoma
2
Plasma cell
2
Lymphoid
2
Classical hematology
2
Other hematologic neoplasm
1
Dermatologic
1
Conditions
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Recurrence
1
Pheochromocytoma
1
Pathologic Complete Response
1
Paraganglioma
1
Osteosarcoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Neoplasms
1
Meningioma
1
Medulloblastoma
1
Hemangiosarcoma
1
Glioma
1
Glioblastoma
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
Breast Neoplasms
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Doxorubicin
25
Cyclophosphamide
24
pembrolizumab
20
Specimen Handling
19
Temozolomide
16
Magnetic Resonance Spectroscopy
15
Surgical Procedures, Operative
14
Radiotherapy
13
Blood Specimen Collection
13
Biopsy
13
atezolizumab
12
Gemcitabine
12
fludarabine
11
Vincristine
11
Ifosfamide
11
X-Rays
8
Trabectedin
8
Nivolumab
8
Irinotecan
8
Imatinib Mesylate
8
Drug Therapy
8
cabozantinib
7
Surveys and Questionnaires
7
Radiation
7
liposomal doxorubicin
5
abemaciclib
5
Sunitinib
5
Standard of Care
5
Radiation Dose Hypofractionation
5
Dactinomycin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
olaparib
×
Sarcoma
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled